Download PDF
Z Gastroenterol 2007; 45(12): 1281-1328
DOI: 10.1055/s-2007-963714
Leitlinie

© Georg Thieme Verlag KG Stuttgart · New York

Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus (HBV) Infection: The German Guidelines for the Management of HBV Infection[1]

Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-(HBV-)InfektionM. Cornberg1 , U. Protzer2 , M. M. Dollinger3 , J. Petersen4 , H. Wedemeyer1 , T. Berg5 , W. Jilg6 , A. Erhardt7 , S. Wirth8 , P. Schirmacher9 , W. E. Fleig10 , M. P. Manns1
  • 1Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
  • 2Institut für Virologie, Technische Universität München/Helmholtz Zentrum München
  • 3Klinik und Poliklinik für Innere Medizin I, Martin-Luther-Universität Halle
  • 4I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf
  • 5Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité, Campus Virchow-Klinikum, Humboldt-Universität zu Berlin
  • 6Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg
  • 7Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf
  • 8Zentrum für Kinder- und Jugendmedizin, HELIOS-Klinikum Wuppertal, Universität Witten/Herdecke
  • 9Pathologisches Institut, Universitätklinikum Heidelberg
  • 10Universitätsklinikum, Universität Leipzig
Further Information

Publication History

Publication Date:
13 December 2007 (online)

Also available at
    Permissions and Reprints

Structure of the guideline

Preface

The update of the S 3-guideline on “prophylaxis, diagnosis, and therapy of hepatitis B virus (HBV) infection” published in 2004 was agreed upon in cooperation with the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Pathology (DGP), the Society for Virology (GfV), the Society for Pediatric Gastroenterology and Nutrition (GPGE), and the Competence Network for Viral Hepatitis (Hep-Net). Seven guideline task forces and an advisory board were established. [Table 1] shows the representatives from the four societies. Members represent the disciplines gastroenterology and hepatology, infectiology, virology, pathology, surgery, and epidemiology. The structure of the German health care system was taken into account by involving doctors who work in hospitals and private practices. The patient organization Deutsche Leberhilfe e. V. represents the patients’ point of view ([Table 2]).

Table 1 Members involved in the guideline preparation TF 1: diagnosis TF 2: indication TF 3: therapy TF 4: transplantation 1. Gerlich, W., Gießen2. Löhr, H., Wiesbaden3. Protzer, U., Munich1 4. Rasenack, J. W. F., Freiburg5. Schaefer, S., Rostock6. Schirmacher, P., Heidelberg7. Treichel, U., Düsseldorf8. Wittekind, C., Leipzig 1. Böcher, W. O., Mainz 2. Cornberg, M., Hannover 3. Dollinger, M., Halle 4. Encke, J., Heidelberg 5. Hüppe, D., Herne 6. Niederau, C., Oberhausen 7. Petersen, J., Hamburg1 8. Tannapfel, A., Bochum 9. van Thiel, I., Cologne10. Wasmuth, H. E., Aachen 1. Böker, K., Hannover 2. Fiedler, M., Essen 3. Göser, T., Cologne 4. Hinrichsen, H., Kiel 5. Kautz, A., Cologne 6. Roeb, E., Gießen 7. Sarrazin, C., Homburg 8. Schlaak, J., Essen 9. Somasundaram, R., Berlin10. von Weizsäcker, F., Berlin11. Wedemeyer, H., Hannover1 12. Zachoval, R., Munich 1. Bahr, M., Hannover 2. Bechstein, W. O., Frankfurt 3. Beckebaum, S., Essen 4. Berg, T., Berlin1 5. Jonas, S., Berlin 6. Kahl, A., Berlin 7. Kasper, H. U., Münster 8. Schlitt, H. J., Regensburg 9. Schmidt, H., Münster10. Sterneck, M., Hamburg11. Tillmann, H. L., Leipzig TF 5: prophylaxis TF 6: co-infections TF 7: children advisory board 1. Burdelski, M., Hamburg2. Heintges, T., Neuss3. Höhler, T., Recklinghausen4. Jilg, W., Regensburg1 5. Kallinowski, B., Schwetzingen6. Radun, D., Berlin7. Spengler, U., Bonn8. Thimme, R., Freiburg 1. Böhm, S., Heidelberg2. Erhardt, A., Düsseldorf1 3. Klinker, H., Würzburg4. Mauss, S., Düsseldorf5. Oette, M., Düsseldorf6. Reiser, M., Bochum/Marl7. Rockstroh, J., Bonn 1. Buderus, S., Bonn 2. Henneke, P., Freiburg 3. Lang, T., Starnberg 4. Melter, M., Regensburg 5. Schmidt-Choudhury, A., Bochum 6. Wirth, S., Wuppertal1 7. Zimmer, K.-P., Gießen 1. Blum, H. E., Freiburg 2. Dienes, H. P., Cologne 3. Fleig, W. E., Leipzig 4. Galle, P., Mainz 5. Gerken, G., Essen 6. Häussinger, D., Düsseldorf 7. Lohse, A., Hamburg 8. Manns, M. P., Hannover 9. Neuhaus, P., Berlin10. Nützenadel, W., Mannheim11. Ramadori, G., Göttingen12. Roggendorf, M., Essen13. Sauerbruch, T., Bonn14. Schmidt, W. E., Bochum15. Schmiegel, W., Bochum16. Stark, K., Berlin17. Trautwein, C., Aaachen18. Zeuzem, S., Frankfurt 1Head of task force. Table 2 Additional concensus conference participants 1. Deterding, K., Hannover2. Dreier, M., Münster (GuV)3. Drebber, U., Cologne4. Kasper, H. U., Münster5. Diepolder, H., Munich6. Csepregi, A., Magdeburg 7. Buggisch, P., Hamburg 8. Hellerbrand, C., Regensburg 9. Herrmann, A., Jena10. Böcker, U., Mannheim11. Hütteroth, T. H., Lübeck12. Kaiser, S., Tübingen 13. Stoehr, A., Hamburg 14. Kronenberger, B., Frankfurt15. Lammert, F., Bonn16. Meyer, S., Hannover17. Müller-Schilling, M., Heidelberg 18. Urban, S., Heidelberg19. van Bömmel F., Berlin

Conflict of interest

While professional expertise is necessary when developing the guideline for health care, a commercial dependency or other conflict of interest which could influence or even systematically distort the guideline contents must be strictly avoided. The statements of the authors and participants of the consensus process are important to evaluate the quality of the guideline. Furthermore, they are important for its overall authorization and credibility as seen by the public and politicians. All persons involved in the guideline preparation have signed a statement on their possible conflict of interest. The signed forms are kept at the office of the Competence Network for Viral Hepatitis ([Table 3]).

Table 3 Financial or other connections or conflict of interest of the authors with third parties who are potentially interested in the guideline contents authors affiliation conflict of interest M. Cornberg consultancy or expertise for (Hope for Hep B) Bristol Myers Squibb; paid lectures for Roche, Novartis, Bristol Myers Squibb, Essex, Falk none U. Protzer none none M. Dollinger paid lectures for Gilead, Roche, Essex, Falk; consultancy for Gambro none J. Petersen consultancy or expertise for Bristol Myers Squibb, Gilead, Idenix, Novartis, Roche, Schering-Plough; paid lectures for Bristol Myers Squibb, Falk, Gilead, Glaxo Smith Kline, Idenix, Novartis, Roche, Schering-Plough. Third party funds from Gilead, GlaxoSmithKline, Schering Plough none H. Wedemeyer consultancy or expertise for Bristol Myers Squibb, Gilead, Novartis, Roche; paid lectures for Bristol Myers Squibb,Gilead, Roche, Novartis, Bristol Myers Squibb, Essex, Falk none T. Berg consultancy or expertise for Bristol Myers Squibb, Roche, Novartis, Idenix, Essex, Gilead, Vertex, Tibotec; lectures for Bristol Myers Squibb, Roche, Novartis, Idenix, Essex, Gilead none W. Jilg paid lecture for GlaxoSmithKline, SanofiPasteur MSD, NovartisBehring none A. Erhardt paid lectures for Roche, Novartis, Bristol Myers Squibb, Essex, Falk, Gilead; third party funds from Roche. none S. Wirth none none P. Schirmacher consultancy for Novartis; paid lectures for Roche, Essex none W. E. Fleig paid lectures for Falk none M. P. Manns consultancy or expertise for Schering Plough, Roche, Bristol Myers Squibb, Gilead, Valeant, Boehringer Ingelheim, Novartis, Idenix; paid lectures for Schering Plough, Roche, Bristol Myers Squibb, Novartis, GlaxoSmithKline, Gilead, Falk; third parts funds from Schering Plough, Roche, Gilead, Novartis, Boehringer Ingelheim none

Aims of the guideline

The aim of this guideline is the establishment of standards for the prophylaxis, diagnosis, and therapy of hepatitis B virus infections to reduce new infections, to use diagnostic testing rationally, to prevent complications of chronic hepatitis, and to use evidence based antiviral therapy. The latter minimizes the development of viral resistance.

This includes a critical appraisal of the clinical and viral diagnostic tests, a transparent stage classification and risk stratification, and the recommendation of a risk adapted antiviral therapy. The aim is to achieve the best possible treatment success in combination with a cost-effective management of the patient.

The S 3-guideline was developed according to the criteria of the workshop of the scientific medical professional societies (AWMF). Its purpose is to achieve “evidence”-based, criteria oriented, high quality medical health care, good handling of hepatitis B virus infection management, as well as rational based medical decisions.

The guideline will give the treating physician rational and “evidence”-based instructions to ensure sufficient, appropriate, and cost-efficient therapy of this disease. It focuses not only on “standard” patients, but also on patients before and after organ transplantation, on patients with co-infections, as well as children and adolescents. Therefore, it offers the basis for solving medical questions and problems pertaining to HBV infections by also using multimodal treatment concepts.

It is intended for all doctors in private practices or hospitals, for nurses, as well as employees of health organizations or persons who are directly and indirectly involved in the treatment and care of patients with hepatitis B virus infections. A guideline for patients will be developed on the basis of this guideline in cooperation with Deutsche Leberhilfe e. V.

We would like to point out that special knowledge is necessary for the management and therapy of chronic HBV infections and should be performed by doctors who are experienced in this area.

Preparation of the guideline

The guideline was developed in several steps. The result of the development process is a three step guideline in the context of a three-step-concept of the task force of scientific medical professional societies ([Table 4]). The main focus is a combined, formal process for finding a consensus consisting of a nominal group and consensus process that was multidisciplinary.

Table 4 Three-step-concept of the guideline preparation of the AWMF 1. Step (S1):expert group A representative expert group of scientific medical professional societies develops in formal consensus a guideline that is passed by the executive board of the professional societies. 2. Step (S2):formal consensus finding Available guidelines from step 1 will be consulted in an established consensus process. It will be passed as a guideline step 2. Formal consensus finding methods are nominal group process, Delphi method, and consensus conference. They include a discussion of the “evidence” for the passed statements. The support of a methodologist is helpful. 3. Step (S3):guideline with all elements of systematic preparation The formal consensus process is extended by the following systematic elements:- logical analysis (clinical algorithm),- “evidence”-based medicine,- decision analysis,- outcome analysis. Literature search After the selection and definition of guideline topics and the outlining of the work program, the authors were delegated a task with a coreviewer. The literature search was done using databases such as Cochrane Library, DIMDI- literature databases-superbases, Medline, NHS-Database PubMed as well as personal reference libraries, internet search engines, and individual searches at the pertinent organizations (university clinics, research institutions, pharmaceutical industry). The pertinent literature was systematically collected, saved, and evaluated according to a standard classification scheme (Table 5). Table 5 The following keywords were used for the literature search3 TF1: diagnosis #1: Hepatitis B or Hepatitis D#2: definition* or (clinical* diagnostic*) or (laboratory* diagnostic*) or imaging* or histopathology* or (therapy monitoring) or (drug resistance)#3 = #1 AND #2 314 abstracts TF2: indication #1: Hepatitis B or Hepatitis D#2: (natural course*) or ((prognosis* or prognostic*) and (factor* or value*) or ((therapeutic* and (aim* or goals*) or (indication*) or (contraindication*)#3 = #1 AND #2 306 abstracts TF3: therapy #1: Hepatitis B or Hepatitis D#2: ((standard therapy) or interferon alpha or lamivudine or adefovir or tenofovir or entecavir or telbivudine or clevudine or emcitricitabine or pegylated or (combination therapy) and (dosis* or dosage* or contraindication or (side effects) or monitoring)#3: #1 AND #2#4: (problem* or HBeAg-negative or alcoholic or (drug* abus*) or (interferon and (non-responder or non-response) or (lamivudine resistan*) or (liver cirrhosis) or (immunosuppression) or h*modialysis or (extrahepatic manifestation*) or (HBV carrier*)#5: #1 AND #4#6: #3 AND #5 153 abstracts TF4: transplantation #1: Hepatitis B or Hepatitis D#2: transplantation or re-infection#3: #1 AND #2 316 abstracts TF5: prophylaxis #1: Hepatitis B or Hepatitis D#2: (immunoprophyla* or vaccin* or (booster and vaccination*)#3: #1 AND #2 790 abstracts TF6: coinfections #1: Hepatitis B or Hepatitis D#2: co-infection and (hcv or hiv or hdv)#3: #1 AND #2 53 abstracts TF7: children and adolescents #1: Hepatitis B or Hepatitis D#2: children* or adolescent*#3: #1 AND #2 470 abstracts 1The respective abstracts were made available to the heads of the TF. Further abstracts some of which were released during the guideline process were chosen in addition by the heads of TF. Altogether 481 publications were evaluated and cited in the text. The classification “evidence” and the level of recommendation were performed according to the Oxford Centre of Evidence Based Medicine (http://www.cebm.net/levels_of_evidence.asp) (Table 6). The literature was evaluated by the head of each task force and synchronized with the coreviewer. In case of discrepancies, a consensus within the task force was achieved, which was authorized in the final consensus conference. Table 6 Classification of the “evidence”: “evidence” level (1 - 5) und recommendation grade (A-D) according to Oxford Centre of Evidence Based Medicine recommendation level “evidence” level description A Ia “evidence” by systematic review of randomized controlled studies (RCT) Ib “evidence” by an appropriately planned RCT Ic all or none principle B IIa “evidence” by systematic review of well planned cohort studies IIb “evidence” by a well planned cohort study/RCT of moderate quality (e. g. < 80 % follow-up) IIc “evidence” by outcome-research-studies IIIa “evidence” by systematic review of well planned case-controlled studies IIIb “evidence” by case-controlled studies C IV “evidence” by case-series/cohort and case-controlled studies of moderate quality D V expert opinion without explicit critical evaluation or based on physiologic models, laboratory research results, or “first principles” Wording of the recommendations After preparation and correction of the manuscripts by the coreviewers, they were revised by the individual guideline task forces and accepted according to majority decision. The proposed recommendations were revised in December 2006 during a Delphi-round which all members of the task force and the advisory board attended. The complete manuscript (preliminary guideline) was made available to all participants (task force members, advisory board, and other participants) before the consensus conference that took place in Göttingen on January 27, 2007. In addition to the persons involved in the guideline process, the ones listed in Table 2 participated. Members of the consensus conference were experts in the disciplines of gastroenterology and hepatology, infectiology, virology, pathology, surgery, and epidemiology. The guideline task force and the consensus conference did not approve an inclusion of the pharmaceutical industry in the guideline development process. Any recommendation of the guideline was authorized via TED-system. Consensus was defined as an approval of 80 %. After review and appraisal of the guideline by leading professional societies, the guideline was authorized as an official announcement by the executive boards of the four professional societies. The preparation of the guideline began on January 27, 2006 and was formally completed on April 21, 2007 (Table 7). Table 7 Development of the guideline “prophylaxis, diagnosis, and therapy of hepatitis B virus (HBV) infection” step I Literature search using keywords in Hep-Net- and DGVS-offices. Viewing of available guidelines (DGVS, DGP, GfV, GPGE, AWMF, AASLD, EASL, ECC, EVHEI, Asian-Pacific consensus statement) step II - preparation of recommendations using an informal consensus within the task forces (Sessions: GASL Conference January 2006, GfV Conference March 2006, Hep-Net Conference June 2006, DGVS Conference September 2006; in addition circulation of the updated electronic version 3times)- phrasing of the guideline by the heads of the task forces (Hannover October 2006, telephone conference November 2006) and Delphi-Conference (task forces, advisory board) December 2006 and January 2007- extended Consensus Conference January 27, 2007 including establishment of the guidelines- authorization of the guideline by professional societies April 2007

Financing

The preparation of the guideline was financed by the professional societies that were involved and the Competence Network for Viral Hepatitis. All members of the task forces volunteered their time and were not paid. They were reimbursed for traveling and other expenses according to the Federal Law on Business Trips or according to the regulations common for Universities. Topics and contents were in no way influenced. Financial support by the pharmaceutical industry was explicitly renounced to achieve best possible independence.

Publication/implementation procedures

The guideline “prophylaxis, diagnosis, and therapy of hepatitis B virus (HBV) infection” will be made known to the professional community in the journal of the professional society DGVS, “Zeitschrift für Gastroenterologie”. In addition, the guideline will be presented on the homepage of the GfV (www.g-f-v.org) and the Competence Network for Viral Hepatitis (www.kompetenznetz-hepatitis.de). It can be downloaded free of charge and will be sent to all associated members (about 1300) of the Competence Network for Viral Hepatitis. Presentations of the guideline at conferences and seminars are planned. The Competence Network for Viral Hepatitis will for example hold CME-certified workshops “Hepatitis B guidelines”. The guideline may also be viewed on the AWMF website (http://leitlinien.net). Short versions will be published in various journals (e. g. Hep-Net News, DMW etc.).

To simplify the practical application using algorithms and cross points, a visualization of the guideline is intended with the help of knowledge Tools®. At each cross point there will be a link to the text of the guideline. In addition, files may be provided with further information (publications, diagrams, product information). Thus, the guideline may also be used for educational purposes. This form of the guideline will be accessible via the internet.

Regular revisions

The guideline is effective until April 30, 2010. It is planned to correct new, relevant, and accepted findings that are in contrast to statements in the guideline immediately in the professional journals. A prompt update of the guideline can also be made using knowledge Tools®.

Guideline evaluation

The implementation of the guidelines is supposed to improve the patients’ prognosis [303]. Since the guideline must formally be viewed as a hypothesis, an evaluation within an appropriate time frame is planned. Suitable from a scientific and organizational stand point are for example the Competence Network for Viral Hepatitis and the German Liver Foundation or the Federal Office for Quality Assurance with external comparative quality assurance according to paragraph 137 SGB V. Possible quality indicators are for example number of identified hepatitis B patients, mortality dependent on severity of disease, or changes in antiviral substance prescription. The patient register of the Competence Network for Viral Hepatitis seems to be suitable for monitoring these factors. A precise evaluation concept will be drawn up by a task force which will be specifically established for this purpose.

1 Original publication: Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-) Infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 2007; 45 (6): 525 - 574.

References

  • 1 Immunisation against hepatitis B.  Lancet. 1988;  1 875-876
    Google Scholar
  • 2 Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity.  Lancet. 2000;  355 561-565
    Google Scholar
  • 3 Ahmed A, Keeffe E B. lamivudinee therapy for chemotherapy-induced reactivation of hepatitis B virus infection.  Am J Gastroenterol. 1999;  94 249-251
    Google Scholar
  • 4 Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients.  Am J Nephrol. 2000;  20 53-56
    Google Scholar
  • 5 Anselmo D M, Ghobrial R M, Jung L C. et al . New era of liver transplantation for hepatitis B: a 17-year single-center experience.  Ann Surg. 2002;  235 611-619
    Google Scholar
  • 6 Arribas J R, Gonzalez-Garcia J J, Lorenzo A. et al . Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain.  AIDS. 2005;  19 1361-1365
    Google Scholar
  • 7 Arslan M, Wiesner R H, Sievers C. et al . Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease.  Liver Transpl. 2001;  7 314-320
    Google Scholar
  • 8 Ascherio A, Zhang S M, Hernan M A. et al . Hepatitis B vaccination and the risk of multiple sclerosis.  N Engl J Med. 2001;  344 327-332
    Google Scholar
  • 9 Averhoff F, Mahoney F, Coleman P. et al . Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection.  Am J Prev Med. 1998;  15 1-8
    Google Scholar
  • 10 Awerkiew S, Daumer M, Reiser M. et al . Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient.  J Clin Virol. 2007;  38 83-86
    Google Scholar
  • 11 Ayoola E A, Johnson A O. Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies to infants.  Int J Gynaecol Obstet. 1987;  25 297-301
    Google Scholar
  • 12 Aziz A, Aziz S, Li D S. et al . Efficacy of repeated high-dose hepatitis B vaccine [80 microg) in patients with chronic liver disease.  J Viral Hepat. 2006;  13 217-221
    Google Scholar
  • 13 Bae S H, Yoon S K, Choi J Y. et al . Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.  J Gastroenterol Hepatol. 2005;  20 1527-1532
    Google Scholar
  • 14 Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory.  Vaccine. 2000;  19 877-885
    Google Scholar
  • 15 Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.  Vaccine. 2006;  24 572-577
    Google Scholar
  • 16 Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients.  J Hepatol. 2006;  44 S90-S94
    Google Scholar
  • 17 Benhamou Y, Bochet M, Thibault V. et al . Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.  Hepatology. 1999;  30 1302-1306
    Google Scholar
  • 18 Benhamou Y, Thibault V, Vig P. et al . Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.  J Hepatol. 2006;  44 62-67
    Google Scholar
  • 19 Benner K G, Lee R G, Keeffe E B. et al . Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation.  Gastroenterology. 1992;  103 1307-1312
    Google Scholar
  • 20 Benvegnu L, Fattovich G, Noventa F. et al . Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study.  Cancer. 1994;  74 2442-2448
    Google Scholar
  • 21 Berger A, Doerr H W, Rabenau H F. et al . High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen.  Intervirology. 2000;  43 71-76
    Google Scholar
  • 22 Bienzle U, Gunther M, Neuhaus R. et al . Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease.  Hepatology. 2003;  38 811-819
    Google Scholar
  • 23 Bodsworth N, Donovan B, Nightingale B N. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.  J Infect Dis. 1989;  160 577-582
    Google Scholar
  • 24 Bodsworth N J, Cooper D A, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state.  J Infect Dis. 1991;  163 1138-1140
    Google Scholar
  • 25 Bortolotti F. Treatment of chronic hepatitis B in children.  J Hepatol. 2003;  39 (Suppl 1] S200-S205,
    Google Scholar
  • 26 Bortolotti F, Guido M, Bartolacci S. et al . Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study.  Hepatology. 2006;  43 556-562
    Google Scholar
  • 27 Bortolotti F, Jara P, Barbera C. et al . Long term effect of alpha interferon in children with chronic hepatitis B.  Gut. 2000;  46 715-718
    Google Scholar
  • 28 Brook G. Prevention of viral hepatitis in HIV co-infection.  J Hepatol. 2006;  44 S104-S107
    Google Scholar
  • 29 Brook M G, Chan G, Yap I. et al . Randomised controlled trial of lymphoblastoid interferon alpha in Europid men with chronic hepatitis B virus infection.  BMJ. 1989;  299 652-656
    Google Scholar
  • 30 Brook M G, McDonald J A, Karayiannis P. et al . Randomised controlled trial of interferon alpha 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.  Gut. 1989;  30 1116-1122
    Google Scholar
  • 31 Bruguera M, Rodicio J L, Alcazar J M. et al . Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients.  Vaccine. 1990;  8 (Suppl) S47-S49
    Google Scholar
  • 32 Brunetto M R, Oliveri F, Coco B. et al . Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.  J Hepatol. 2002;  36 263-270
    Google Scholar
  • 33 Buti M, Jardi R, Allende H. et al . Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections?.  J Med Virol. 1996;  49 66-69
    Google Scholar
  • 34 Bzowej N, Chan H L, Lai C L. et al . A randomized trial of telbivudine vs adefovir for HBeAg-positive chronic hepatitis B.  Hepatology. 2006;  44 563A
    Google Scholar
  • 35 Cacciola I, Pollicino T, Squadrito G. et al . Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.  N Engl J Med. 1999;  341 22-26
    Google Scholar
  • 36 Cardell K, Fryden A, Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise.  Scand J Infect Dis. 1999;  31 197-200
    Google Scholar
  • 37 Caredda F, Rossi E, d"Arminio M A. et al . Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome.  J Infect Dis. 1985;  151 925-928
    Google Scholar
  • 38 Carlsson T, Struve J, Sonnerborg A. et al . The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination.  Scand J Infect Dis. 1999;  31 93-95
    Google Scholar
  • 39 Castells L, Vargas V, Rodriguez F. et al . Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.  Liver Transpl. 2002;  8 892-900
    Google Scholar
  • 40 Castelnau C, Le G al F, Ripault M P. et al . Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.  Hepatology. 2006;  44 728-735
    Google Scholar
  • 41 CDC . Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis. Electronic Citation.  2004;  , www.cdc.gov/ncidod/diseases/hepatitis/b/hbv_ms.pdf
    Google Scholar
  • 42 Chalasani N, Smallwood G, Halcomb J. et al . Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?.  Liver Transpl Surg. 1998;  4 128-132
    Google Scholar
  • 43 Chan H L, Leung N W, Hui A Y. et al . A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.  Ann Intern Med. 2005;  142 240-250
    Google Scholar
  • 44 Chan H L, Tang J L, Tam W. et al . The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis.  Aliment Pharmacol Ther. 2001;  15 1899-1905
    Google Scholar
  • 45 Chang T T, Gish R G, Man de R. et al . A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.  N Engl J Med. 2006;  354 1001-1010
    Google Scholar
  • 46 Chang T T, Shiffman M, Tong M. et al . Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB).  Journal of Hepatology. 2004;  40 126
    Google Scholar
  • 47 Charest A F, McDougall J, Goldstein M B. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients.  Am J Kidney Dis. 2000;  36 976-982
    Google Scholar
  • 48 Chen C J, Yang H I, Su J. et al . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.  JAMA. 2006;  295 65-73
    Google Scholar
  • 49 Chen G, Lin W, Shen F. et al . Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.  Am J Gastroenterol. 2006;  101 1797-1803
    Google Scholar
  • 50 Chen J C, Chang M L, Lin J N. et al . Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area.  World J Gastroenterol. 2005;  11 5289-5294
    Google Scholar
  • 51 Chen P M, Chiou T J, Fan F S. et al . Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation.  Transplantation. 1999;  67 1425-1433
    Google Scholar
  • 52 Chen P M, Fan S, Liu C J. et al . Changing of hepatitis B virus markers in patients with bone marrow transplantation.  Transplantation. 1990;  49 708-713
    Google Scholar
  • 53 Chen Y C, Sheen I S, Chu C M. et al . Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.  Gastroenterology. 2002;  123 1084-1089
    Google Scholar
  • 54 Cheng A L. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkins lymphoma.  Blood. 1996;  87 1202
    Google Scholar
  • 55 Cheng A L, Hsiung C A, Su I J. et al . Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.  Hepatology. 2003;  37 1320-1328
    Google Scholar
  • 56 Chien R N, Yeh C T, Tsai S L. et al . Determinants for sustained HBeAg response to lamivudine therapy.  Hepatology. 2003;  38 1267-1273
    Google Scholar
  • 57 Christensen C, Bruden D, Livingston S. et al . Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients.  J Viral Hepat. 2006;  13 652-658
    Google Scholar
  • 58 Chu C M, Liaw Y F. Hepatitis B virus-related cirrhosis: natural history and treatment.  Semin Liver Dis. 2006;  26 142-152
    Google Scholar
  • 59 Chu C M, Yeh C T, Liaw Y F. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus.  Gut. 1999;  45 613-617
    Google Scholar
  • 60 Chuang W L, Dai C Y, Chang W Y. et al . Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.  Antivir Ther. 2005;  10 125-133
    Google Scholar
  • 61 Clark F L, Drummond M W, Chambers S. et al . Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin"s lymphoma.  Ann Oncol. 1998;  9 385-387
    Google Scholar
  • 62 Clemens R, Sanger R, Kruppenbacher J. et al . Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance.  Vaccine. 1997;  15 349-352
    Google Scholar
  • 63 Coates T, Wilson R, Patrick G. et al . Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines.  Clin Ther. 2001;  23 392-403
    Google Scholar
  • 64 Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine.  Nephron. 1976;  16 31-41
    Google Scholar
  • 65 Cohard M, Poynard T, Mathurin P. et al . Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis.  Hepatology. 1994;  20 1390-1398
    Google Scholar
  • 66 Colloredo G, Bellati G, Leandro G. et al . Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new “gray-zone” for the evaluation of “borderline” values.  J Hepatol. 1996;  25 644-648
    Google Scholar
  • 67 Colloredo M G, Bellati G, Leandro G. et al . Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations.  Arch Virol. 1993;  Suppl 8 203-211
    Google Scholar
  • 68 Colonno R J, Rose R, Baldick C J. et al . Entecavir resistance is rare in nucleoside naive patients with hepatitis B.  Hepatology. 2006;  44 1656-1665
    Google Scholar
  • 69 Colonno R J, Rose R E, Pokornowski K. et al . Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients.  Hepatology. 2006;  44 229A-230A
    Google Scholar
  • 70 Confavreux C, Suissa S, Saddier P. et al . Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.  N Engl J Med. 2001;  344 319-326
    Google Scholar
  • 71 Cooksley W G. Treatment with interferons (including pegylated interferons) in patients with hepatitis B.  Semin Liver Dis. 2004;  24 (Suppl 1] 45-53
    Google Scholar
  • 72 Cooksley W G, Piratvisuth T, Lee S D. et al . Peginterferon alpha-2a [40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.  J Viral Hepat. 2003;  10 298-305
    Google Scholar
  • 73 Cortelezzi A, Vigano M, Zilioli V R. et al . Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1&SIXSP;H.  J Clin Virol. 2006;  35 467-469
    Google Scholar
  • 74 Cotonat T, Quiroga J A, Lopez-Alcorocho J M. et al . Pilot study of combination therapy with ribavirin and interferon alpha for the retreatment of chronic hepatitis B e antibody-positive patients.  Hepatology. 2000;  31 502-506
    Google Scholar
  • 75 Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B.  J Hepatol. 2003;  39 (Suppl 1] S99-S105
    Google Scholar
  • 76 Crespo J, Fabrega E, Casafont F. et al . Severe clinical course of de novo hepatitis B infection after liver transplantation.  Liver Transpl Surg. 1999;  5 175-183
    Google Scholar
  • 77 Crespo J, Lozano J L, Echevarria S. et al . Influence of hepatitis C virus infection and human immunodeficiency on the natural history of chronic delta hepatitis.  Rev Esp Enferm Dig. 1994;  85 185-191
    Google Scholar
  • 78 D"Antiga L, Aw M, Atkins M. et al . Combined lamivudine/interferon-alpha treatment in “immunotolerant” children perinatally infected with hepatitis B: a pilot study.  J Pediatr. 2006;  148 228-233
    Google Scholar
  • 79 Dahmen A, Herzog-Hauff S, Bocher W O. et al . Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.  J Med Virol. 2002;  66 452-460
    Google Scholar
  • 80 Dai M S, Chao T Y. lamivudinee therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?.  Breast Cancer Res Treat. 2005;  92 95-96
    Google Scholar
  • 81 Dai M S, Wu P F, Lu J J. et al . Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study.  Support Care Cancer. 2004;  12 191-196
    Google Scholar
  • 82 Davies S E, Portmann B C, O"Grady J G. et al . Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.  Hepatology. 2004;  13 150-157
    Google Scholar
  • 83 De Feo T M, Poli F, Mozzi F. et al . Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study.  Transplant Proc. 2005;  37 1238-1239
    Google Scholar
  • 84 De Maria N, Colantoni A, Friedlander L. et al . The impact of previous HBV infection on the course of chronic hepatitis C.  Am J Gastroenterol. 2000;  95 3529-3536
    Google Scholar
  • 85 del Canho R, Grosheide P M, Mazel J A. et al . Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982 - 1992: protective efficacy and long-term immunogenicity.  Vaccine. 1997;  15 1624-1630
    Google Scholar
  • 86 del Canho R, Grosheide P M, Voogd M. et al . Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes.  J Med Virol. 1993;  41 30-34
    Google Scholar
  • 87 Delaugerre C, Marcelin A G, Thibault V. et al . Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.  Antimicrob Agents Chemother. 2002;  46 1586-1588
    Google Scholar
  • 88 Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.  N Engl J Med. 2001;  344 68-69
    Google Scholar
  • 89 Deutsch J, Wirth S. Konsensus über die Behandlung der chronischen Hepatitis B im Kindesalter.  Monatsschr Kinderheilkd. 2002;  150 625-629
    Google Scholar
  • 90 Dhedin N, Douvin C, Kuentz M. et al . Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.  Transplantation. 1998;  66 616-619
    Google Scholar
  • 91 Di Bisceglie A, Lai C L, Gane E. et al . Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients.  Hepatology. 2006;  44 230A-231A
    Google Scholar
  • 92 Di Marco V, Giacchino R, Timitilli A. et al . Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.  J Viral Hepat. 1996;  3 123-128
    Google Scholar
  • 93 Di Marco V, Marzano A, Lampertico P. et al . Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.  Hepatology. 2004;  40 883-891
    Google Scholar
  • 94 Di Martino V, Lunel F, Cadranel J F. et al . Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B.  J Viral Hepat. 1996;  3 253-260
    Google Scholar
  • 95 Di Martino V, Thevenot T, Boyer N. et al . Serum alanine transaminase level is a good predictor of response to interferon alpha therapy for chronic hepatitis B in human immunodeficiency virus-infected patients.  Hepatology. 2000;  31 1030-1031
    Google Scholar
  • 96 Di Martino V, Thevenot T, Colin J F. et al . Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.  Gastroenterology. 2002;  123 1812-1822
    Google Scholar
  • 97 Dickson R C, Everhart J E, Lake J R. et al . Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.  Gastroenterology. 1997;  113 1668-1674
    Google Scholar
  • 98 Dienstag J L. The role of liver biopsy in chronic hepatitis C.  Hepatology. 2002;  36 S152-S160
    Google Scholar
  • 99 Dienstag J L. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B.  J Hepatol. 2005;  42 158-162
    Google Scholar
  • 100 Dienstag J L, Cianciara J, Karayalcin S. et al . Durability of serologic response after lamivudine treatment of chronic hepatitis B.  Hepatology. 2003;  37 748-755
    Google Scholar
  • 101 Dienstag J L, Schiff E R, Wright T L. et al . lamivudinee as initial treatment for chronic hepatitis B in the United States.  N Engl J Med. 1999;  341 1256-1263
    Google Scholar
  • 102 Dikici B, Bosnak M, Bosnak V. et al . Combination therapy for children with chronic hepatitis B virus infection.  J Gastroenterol Hepatol. 2002;  17 1087-1091
    Google Scholar
  • 103 Dikici B, Ozgenc F, Kalayci A G. et al . Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study.  J Gastroenterol Hepatol. 2004;  19 127-133
    Google Scholar
  • 104 Dore G J, Cooper D A, Barrett C. et al . Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.  J Infect Dis. 1999;  180 607-613
    Google Scholar
  • 105 Douglas D D, Rakela J, Wright T L. et al . The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient.  Liver Transpl Surg. 1997;  3 105-111
    Google Scholar
  • 106 Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B.  Expert Opin Drug Saf. 2003;  2 225-231
    Google Scholar
  • 107 Endo T, Sakai T, Fujimoto K. et al . A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin"s lymphoma.  Bone Marrow Transplant. 2001;  27 433-436
    Google Scholar
  • 108 Erhardt A, Blondin D, Hauck K. et al . Response to interferon alpha is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.  Gut. 2005;  54 1009-1013
    Google Scholar
  • 109 Erhardt A, Gerlich W, Starke C. et al . Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.  Liver Int. 2006;  26 805-810
    Google Scholar
  • 110 Erhardt A, Sagir A, Guillevin L. et al . Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine.  J Hepatol. 2000;  33 677-683
    Google Scholar
  • 111 Evans T G, Schiff M, Graves B. et al . The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.  Clin Nephrol. 2000;  54 138-142
    Google Scholar
  • 112 Fabrizi F, Martin P, Dixit V. et al . HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies.  Am J Transplant. 2005;  5 2913-2921
    Google Scholar
  • 113 Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage.  J Nephrol. 2002;  15 605-613
    Google Scholar
  • 114 Farci P, Mandas A, Coiana A. et al . Treatment of chronic hepatitis D with interferon alpha-2a.  N Engl J Med. 1994;  330 88-94
    Google Scholar
  • 115 Farci P, Roskams T, Chessa L. et al . Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.  Gastroenterology. 2004;  126 1740-1749
    Google Scholar
  • 116 Farci P, Smedile A, Lavarini C. et al . Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity.  Gastroenterology. 1983;  85 669-673
    Google Scholar
  • 117 Farrell G C. Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation?.  J Gastroenterol Hepatol. 1999;  14 741-744
    Google Scholar
  • 118 Fattovich G, Boscaro S, Noventa F. et al . Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.  J Infect Dis. 1987;  155 931-935
    Google Scholar
  • 119 Fattovich G, Brollo L, Boscaro S. et al . Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.  J Hepatol. 1989;  9 331-937
    Google Scholar
  • 120 Fattovich G, Giustina G, Christensen E. et al . Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).  Gut. 2000;  46 420-426
    Google Scholar
  • 121 Firpi R J, Nelson D R. Viral hepatitis: manifestations and management strategy.  Hematology Am Soc Hematol Educ Program. 2006;  375-380
    Google Scholar
  • 122 Flink H J, Zonneveld van M, Hansen B E. et al . Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.  Am J Gastroenterol. 2006;  101 297-303
    Google Scholar
  • 123 Floreani A, Boninsegna S, Lobello S. et al . Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal.  Gastroenterol Clin Biol. 2006;  30 307-309
    Google Scholar
  • 124 Fontana R J, Hann H W, Perrillo R P. et al . Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.  Gastroenterology. 2002;  123 719-727
    Google Scholar
  • 125 Fontana R J, Keeffe E B, Carey W. et al . Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.  Liver Transpl. 2002;  8 433-439
    Google Scholar
  • 126 Fornairon S, Pol S, Legendre C. et al . The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection.  Transplantation. 1996;  62 297-299
    Google Scholar
  • 127 Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation.  Bone Marrow Transplant. 2006;  37 625-626
    Google Scholar
  • 128 Fukuda R, Ishimura N, Kushiyama Y. et al . Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver.  J Hepatol. 1997;  26 455-461
    Google Scholar
  • 129 Fung S K, Chae H B, Fontana R J. et al . Virologic response and resistance to adefovir in patients with chronic hepatitis B.  J Hepatol. 2006;  44 283-290
    Google Scholar
  • 130 Fung S K, Wong F, Hussain M. et al . Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.  J Viral Hepat. 2004;  11 432-438
    Google Scholar
  • 131 Fytili P, Ciesek S, Manns M P. et al . Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients.  Transplantation. 2006;  81 808-809
    Google Scholar
  • 132 Gan S I, Devlin S M, Scott-Douglas N W. et al . lamivudinee for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection.  Can J Gastroenterol. 2005;  19 625-629
    Google Scholar
  • 133 Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation.  Transplantation. 2002;  74 427-437
    Google Scholar
  • 134 Ganem D, Prince A M. Hepatitis B virus infection - natural history and clinical consequences.  N Engl J Med. 2004;  350 1118-1129
    Google Scholar
  • 135 Garripoli A, Di Marco V, Cozzolongo R. et al . Ribavirin treatment for chronic hepatitis D: a pilot study.  Liver. 1994;  14 154-157
    Google Scholar
  • 136 Gaudin J L, Trepo C. Therapy of chronic delta hepatitis with alpha- and beta-interferon.  Prog Clin Biol Res. 1993;  382 345-352
    Google Scholar
  • 137 Geier M R, Geier D A. Immunologic reactions and hepatitis B vaccine.  Ann Intern Med. 2001;  134 1155
    Google Scholar
  • 138 Gerlich W H, Thomssen R. Terminology, structure and laboratory diagnosis of hepatitis viruses. Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rhodes J Oxford Textbook of Clinical Hepatology Oxford; Oxford University press 1999: 828-869
    Google Scholar
  • 139 Ghany M G, Ayola B, Villamil F G. et al . Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.  Hepatology. 1998;  27 213-222
    Google Scholar
  • 140 Gigliotti A R, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation.  J Pediatr Hematol Oncol. 2003;  25 184-192
    Google Scholar
  • 141 Girard M. Autoimmune hazards of hepatitis B vaccine.  Autoimmun Rev. 2005;  4 96-100
    Google Scholar
  • 142 Gish R G, Chang T T, Man R A. et al . Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022].  Hepatology. 2005;  42 267A-268A
    Google Scholar
  • 143 Govindarajan de S, Chin K P, Redeker A G. et al . Fulminant B viral hepatitis: role of delta agent.  Gastroenterology. 1984;  86 1417-1420
    Google Scholar
  • 144 Gregorio G V, Jara P, Hierro L. et al . Lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.  Hepatology. 1996;  23 700-707
    Google Scholar
  • 145 Grob P, Jilg W, Bornhak H. et al . Serological pattern “anti-HBc alone”: report on a workshop.  J Med Virol. 2000;  62 450-455
    Google Scholar
  • 146 Gunsar F, Akarca U S, Ersoz G. et al . Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.  Antivir Ther. 2005;  10 721-726
    Google Scholar
  • 147 Hadler S C, Alcala d M, Rivero D. et al . Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela.  Am J Epidemiol. 1992;  136 1507-1516
    Google Scholar
  • 148 Hadler S C, Monzon de M, Ponzetto A. et al . Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela.  Ann Intern Med. 1984;  100 339-344
    Google Scholar
  • 149 Hadler S C, Francis D P, Maynard J E. et al . Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.  N Engl J Med. 1986;  315 209-214
    Google Scholar
  • 150 Hadler S C, Judson F N, O"Malley P M. et al . Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection.  J Infect Dis. 1991;  163 454-459
    Google Scholar
  • 151 Hadziyannis S J, Papatheodoridis G V, Dimou E. et al . Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.  Hepatology. 2000;  32 847-851
    Google Scholar
  • 152 Hadziyannis S J, Sevastianos V, Rapti I. et al . Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil treatment in HBeAg-negative chronic hepatitis B.  Hepatology. 2006;  44 231A
    Google Scholar
  • 153 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.  N Engl J Med. 2005;  352 2673-2681
    Google Scholar
  • 154 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years.  Gastroenterology. 2006;  131 1743-1751
    Google Scholar
  • 155 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.  N Engl J Med. 2003;  348 800-807
    Google Scholar
  • 156 Hartman C, Berkowitz D, Eshach-Adiv O. et al . Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon.  J Pediatr Gastroenterol Nutr. 2006;  43 494-498
    Google Scholar
  • 157 Hartwig M G, Patel V, Palmer S M. et al . Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation.  Transplantation. 2005;  80 320-325
    Google Scholar
  • 158 Hasselhorn H M, Kralj N, Hofmann F. et al . Non- and low-response after preventive hepatitis B vaccination.  Gesundheitswesen. 1997;  59 321-328
    Google Scholar
  • 159 Heintges T, Petry W, Kaldewey M. et al . Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B.  Dig Dis Sci. 2001;  46 901-906
    Google Scholar
  • 160 Henderson E A, Louie T J, Ramotar K. et al . Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers.  Infect Control Hosp Epidemiol. 2000;  21 264-269
    Google Scholar
  • 161 Hernan M A, Jick S S, Olek M J. et al . Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study.  Neurology. 2004;  63 838-842
    Google Scholar
  • 162 Hillis W D, Hillis A, Walker W G. Hepatitis B surface antigenemia in renal transplant recipients. Increased mortality risk.  JAMA. 1979;  242 329-332
    Google Scholar
  • 163 Hoff J, Bani-Sadr F, Gassin M. et al . Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.  Clin Infect Dis. 2001;  32 963-969
    Google Scholar
  • 164 Hom X, Little N R, Gardner S D. et al . Predictors of virologic response to lamivudinee treatment in children with chronic hepatitis B infection.  Pediatr Infect Dis J. 2004;  23 441-445
    Google Scholar
  • 165 Hoofnagle J H, Seeff L B. Peginterferon and ribavirin for chronic hepatitis C.  N Engl J Med. 2006;  355 2444-2451
    Google Scholar
  • 166 Housset C, Pol S, Carnot F. et al . Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus.  Hepatology. 1992;  15 578-583
    Google Scholar
  • 167 Hsu Y S, Chien R N, Yeh C T. et al . Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.  Hepatology. 2002;  35 1522-1527
    Google Scholar
  • 168 Hui A Y, Chan H L, Cheung A Y. et al . Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon.  Aliment Pharmacol Ther. 2005;  22 519-528
    Google Scholar
  • 169 Hui C K, Cheung W W, Au W Y. et al . Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.  Gut. 2005;  54 1597-1603
    Google Scholar
  • 170 Hui C K, Cheung W W, Zhang H Y. et al . Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.  Gastroenterology. 2006;  131 59-68
    Google Scholar
  • 171 Hui C K, Lau E, Wu H. et al . Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection.  J Clin Virol. 2006;  35 185-192
    Google Scholar
  • 172 Huo T I, Wu J C, Lai C R. et al . Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection.  J Hepatol. 1996;  25 439-444
    Google Scholar
  • 173 Iannitto E, Minardi V, Calvaruso G. et al . Hepatitis B virus reactivation and alemtuzumab therapy.  Eur J Haematol. 2005;  74 254-258
    Google Scholar
  • 174 Idilman R, Arat M, Soydan E. et al . lamivudinee prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.  J Viral Hepat. 2004;  11 141-147
    Google Scholar
  • 175 Idilman R, Colantoni A, De Maria N. et al . Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals.  Hepatogastroenterology. 2003;  50 217-221
    Google Scholar
  • 176 Ikeda K, Shiga Y, Takahashi A. et al . Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.  Leuk Lymphoma. 2006;  47 155-157
    Google Scholar
  • 177 Ilan Y, Ashur Y, Tur-Kaspa R. et al . Chronic hepatitis C virus infection with exposure to hepatitis B virus.  Isr J Med Sci. 1994;  30 259-263
    Google Scholar
  • 178 Iloeje U H, Yang H I, Su J. et al . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.  Gastroenterology. 2006;  130 678-686
    Google Scholar
  • 179 Imbert-Bismut F, Ratziu V, Pieroni L. et al . Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.  Lancet. 2001;  357 1069-1075
    Google Scholar
  • 180 Institute of Medicine - Report . Hepatitis B vaccine and demyelinating neurological disorders. Electronic Citation.  2002;  , www.cdc.gov/nip/vaccine/hep/hepb/iom.htm
    Google Scholar
  • 181 Iwai K, Tashima M, Itoh M. et al . Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient, reactivation of dormant virus during the immunosuppressive period.  Bone Marrow Transplant. 2000;  25 105-108
    Google Scholar
  • 182 Jang J W, Choi J Y, Bae S H. et al . Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma.  J Hepatol. 2004;  41 427-435
    Google Scholar
  • 183 Jang J W, Choi J Y, Bae S H. et al . A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization.  Hepatology. 2006;  43 233-240
    Google Scholar
  • 184 Janssen H L, Zonneveld van M, Senturk H. et al . Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.  Lancet. 2005;  365 123-129
    Google Scholar
  • 185 Janssen H L, Zonneveld van M, Nunen A B. et al . Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome.  Eur J Gastroenterol Hepatol. 2004;  16 801-807
    Google Scholar
  • 186 Jardi van R, Rodriguez F, Buti M. et al . Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference.  Hepatology. 2001;  34 404-410
    Google Scholar
  • 187 Jilg W, Hottentrager B, Weinberger K. et al . Prevalence of markers of hepatitis B in the adult German population.  J Med Virol. 2001;  63 96-102
    Google Scholar
  • 188 Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine.  Infection. 1989;  17 70-76
    Google Scholar
  • 189 Jilg W, Schmidt M, Deinhardt F. Inoculation failure following hepatitis B vaccination. The effect of additional vaccinations.  Dtsch Med Wochenschr. 1990;  115 1545-1548
    Google Scholar
  • 190 Jonas M M, Mizerski J, Badia I B. et al . Clinical trial of lamivudine in children with chronic hepatitis B.  N Engl J Med. 2002;  346 1706-1713
    Google Scholar
  • 191 Kanaan N, Horsmans Y, Goffin E. lamivudinee for nephrotic syndrome related to hepatitis B virus (HBV) infection.  Clin Nephrol. 2006;  65 208-210
    Google Scholar
  • 192 Kanwal F, Farid M, Martin P. et al . Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.  Am J Gastroenterol. 2006;  101 2076-2089
    Google Scholar
  • 193 Kapoor D, Aggarwal S R, Singh N P. et al . Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients.  J Viral Hepat. 1999;  6 405-409
    Google Scholar
  • 194 Kapoor D, Guptan R C, Wakil S M. et al . Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.  J Hepatol. 2000;  33 308-312
    Google Scholar
  • 195 Kelly D. Viral hepatitis in children.  Adv Exp Med Biol. 2004;  549 83-90
    Google Scholar
  • 196 Kempinska A, Kwak E J, Angel J B. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature.  Clin Infect Dis. 2005;  41 1277-1282
    Google Scholar
  • 197 Kim K H, Ahn S H, Chung H Y. et al . Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity.  J Gastroenterol Hepatol. 2004;  19 847-53
    Google Scholar
  • 198 Knoll A, Boehm S, Hahn J. et al . Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation.  Bone Marrow Transplant. 2004;  33 925-929
    Google Scholar
  • 199 Knoll A, Hartmann A, Hamoshi H. et al . Serological pattern “anti-HBc alone”: characterization of 552 individuals and clinical significance.  World J Gastroenterol. 2006;  12 1255-1260
    Google Scholar
  • 200 Kohmoto M, Enomoto M, Tamori A. et al . Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.  J Med Virol. 2005;  75 235-239
    Google Scholar
  • 201 Kondili L A, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases).  J Viral Hepat. 2004;  11 427-431
    Google Scholar
  • 202 Konopnicki D, Mocroft A, Wit de S. et al . Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.  AIDS. 2005;  19 593-601
    Google Scholar
  • 203 Korenman J, Baker B, Waggoner J. et al . Long-term remission of chronic hepatitis B after alpha-interferon therapy.  Ann Intern Med. 1991;  114 629-634
    Google Scholar
  • 204 Kruger M, Boker K H, Zeidler H. et al . Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alpha-2b.  J Hepatol. 1997;  26 935-939
    Google Scholar
  • 205 Kumagai K, Takagi T, Nakamura S. et al . Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.  Ann Oncol. 1997;  8 (Suppl 1] 107-109
    Google Scholar
  • 206 Kumar M, Satapathy S, Monga R. et al . A randomized controlled trial of lamivudine to treat acute hepatitis B.  Hepatology. 2007;  45 97-101
    Google Scholar
  • 207 Kuo A, Dienstag J L, Chung R T. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.  Clin Gastroenterol Hepatol. 2004;  2 266-272
    Google Scholar
  • 208 Lackner H, Moser A, Benesch M. et al . Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy.  J Clin Virol. 2002;  25 (Suppl 3] S73-S79
    Google Scholar
  • 209 Lai C L, Chien R N, Leung N W. et al . A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis lamivudinee Study Group.  N Engl J Med. 1998;  339 61-68
    Google Scholar
  • 210 Lai C L, Dienstag J, Schiff E. et al . Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.  Clin Infect Dis. 2003;  36 687-696
    Google Scholar
  • 211 Lai C L, Gane E, Hsu C W. et al . Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs lamivudine.  Hepatology. 2006;  44 222A
    Google Scholar
  • 212 Lai C L, Gane E, Liaw Y F. et al . Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: First-year results from the international phase III globe trial.  Hepatology. 2005;  42 748A
    Google Scholar
  • 213 Lai C L, Leung N, Teo E K. et al . A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.  Gastroenterology. 2005;  129 528-536
    Google Scholar
  • 214 Lai C L, Shouval D, Lok A S. et al . Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.  N Engl J Med. 2006;  354 1011-1020
    Google Scholar
  • 215 Lampertico P, Del Ninno E, Vigano M. et al . Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.  Hepatology. 2003;  37 756-763
    Google Scholar
  • 216 Lampertico P, Marzano A, Levrero M. et al . Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B.  Hepatology. 2006;  44 693A-694A
    Google Scholar
  • 217 Lampertico P, Vigano M, Manenti E. et al . Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.  Hepatology. 2005;  42 1414-1419
    Google Scholar
  • 218 Lang M, Neumann U, Kahl A. et al . Long-term outcome of 27 patients after combined liver-kidney transplantation.  Transplant Proc. 2001;  33 1440-1441
    Google Scholar
  • 219 Lau D T, Doo E, Park Y. et al . lamivudinee for chronic delta hepatitis.  Hepatology. 1999;  30 546-549
    Google Scholar
  • 220 Lau D T, Everhart J, Kleiner D E. et al . Long-term follow-up of patients with chronic hepatitis B treated with interferon alpha.  Gastroenterology. 1997;  113 1660-1667
    Google Scholar
  • 221 Lau D T, Kleiner D E, Park Y. et al . Resolution of chronic delta hepatitis after 12 years of interferon alpha therapy.  Gastroenterology. 1999;  117 1229-1233
    Google Scholar
  • 222 Lau G K, He M L, Fong D Y. et al . Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.  Hepatology. 2002;  36 702-709
    Google Scholar
  • 223 Lau G K, Liang R, Chiu E K. et al . Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.  Bone Marrow Transplant. 1997;  19 795-799
    Google Scholar
  • 224 Lau G K, Lok A S, Liang R H. et al . Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer.  Hepatology. 1997;  25 1497-1501
    Google Scholar
  • 225 Lau G K, Piratvisuth T, Luo K X. et al . Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.  N Engl J Med. 2005;  352 2682-2695
    Google Scholar
  • 226 Lau G K, Suri D, Liang R. et al . Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen.  Gastroenterology. 2002;  122 614-624
    Google Scholar
  • 227 Lau G K, Yiu H H, Fong D Y. et al . Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.  Gastroenterology. 2003;  125 1742-1749
    Google Scholar
  • 228 Lau J Y, Smith H M, Chaggar K. et al . Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection.  J Med Virol. 1991;  33 273-276
    Google Scholar
  • 229 Laubscher B, Gehri M, Roulet M. et al . Survival of infantile fulminant hepatitis B and treatment with lamivudinee.  J Pediatr Gastroenterol Nutr. 2005;  40 518-520
    Google Scholar
  • 230 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.  J Viral Hepat. 2004;  11 97-107
    Google Scholar
  • 231 Law J K, Ho J K, Hoskins P J. et al . Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.  Leuk Lymphoma. 2005;  46 1085-1089
    Google Scholar
  • 232 Le Gal F, Gordien E, Affolabi D. et al . Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients.  J Clin Microbiol. 2005;  43 2363-2369
    Google Scholar
  • 233 Leaw S J, Yen C J, Huang W T. et al . Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.  Ann Hematol. 2004;  83 270-275
    Google Scholar
  • 234 Lee C, Gong Y, Brok J. et al . Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis.  BMJ. 2006;  332 328-336
    Google Scholar
  • 235 Lee C, Gong Y, Brok J. et al . Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers.  Cochrane Database Syst Rev. 2006;  CD004790
    Google Scholar
  • 236 Lee G W, Ryu M H, Lee J L. et al . The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin"s lymphoma who receive cytotoxic chemotherapy.  J Korean Med Sci. 2003;  18 849-854
    Google Scholar
  • 237 Lee K M, Cho S W, Kim S W. et al . Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion.  J Viral Hepat. 2002;  9 208-212
    Google Scholar
  • 238 Lee W C, Wu M J, Cheng C H. et al . lamivudinee is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.  Am J Kidney Dis. 2001;  38 1074-1081
    Google Scholar
  • 239 Lee Y S, Suh D J, Lim Y S. et al . Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.  Hepatology. 2006;  43 1385-1391
    Google Scholar
  • 240 Li Y H, He Y F, Jiang W Q. et al . lamivudinee prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.  Cancer. 2006;  106 1320-1325
    Google Scholar
  • 241 Liao S S, Li R C, Li H. et al . Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children.  Vaccine. 1999;  17 2661-2666
    Google Scholar
  • 242 Liaw Y F. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.  Semin Liver Dis. 2005;  25 (Suppl 1] 40-47
    Google Scholar
  • 243 Liaw Y F, Chen Y C, Sheen I S. et al . Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.  Gastroenterology. 2004;  126 1024-1029
    Google Scholar
  • 244 Liaw Y F, Chien R N, Yeh C T. No benefit to continue lamivudine therapy after emergence of YMDD mutations.  Antivir Ther. 2004;  9 257-262
    Google Scholar
  • 245 Liaw Y F, Leung N W, Chang T T. et al . Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis lamivudinee Study Group.  Gastroenterology. 2000;  119 172-180
    Google Scholar
  • 246 Liaw Y F, Sung J J, Chow W C. et al . lamivudinee for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 1521-1531
    Google Scholar
  • 247 Liaw Y F, Tsai S L, Sheen I S. et al . Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers.  Am J Gastroenterol. 1998;  93 354-359
    Google Scholar
  • 248 Lim L L, Wai C T, Lee Y M. et al . Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients.  Aliment Pharmacol Ther. 2002;  16 1939-1944
    Google Scholar
  • 249 Lim S G, Krastev Z, Ng T M. et al . Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.  Antimicrob Agents Chemother. 2006;  50 1642-1648
    Google Scholar
  • 250 Lin C C, Chen C L, Concejero A. et al . Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients.  Am J Transplant. 2007;  7 195-200
    Google Scholar
  • 251 Lin S M, Sheen I S, Chien R N. et al . Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology. 1999;  29 971-975
    Google Scholar
  • 252 Lin S M, Yu M L, Lee C M. et al . Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.  J Hepatol. 2007;  46 45-52
    Google Scholar
  • 253 Lo C M, Liu C L, Lau G K. et al . Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.  Liver Transpl. 2005;  11 807-813
    Google Scholar
  • 254 Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy.  Semin Liver Dis. 2005;  25 (Suppl 1] 9-19
    Google Scholar
  • 255 Locarnini S, Hatzakis A, Heathcote J. et al . Management of antiviral resistance in patients with chronic hepatitis B.  Antivir Ther. 2004;  9 679-693
    Google Scholar
  • 256 Lok A S, Lai C L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children.  Hepatology. 1988;  8 1130-1133
    Google Scholar
  • 257 Lok A S, Lai C L, Leung N. et al . Long-term safety of lamivudine treatment in patients with chronic hepatitis B.  Gastroenterology. 2003;  125 1714-1722
    Google Scholar
  • 258 Lok A S, Liang R H, Chiu E K. et al . Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.  Gastroenterology. 1991;  100 182-188
    Google Scholar
  • 259 Lok A S, McMahon B J. AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines.  Rom J Gastroenterol. 2004;  13 150-154
    Google Scholar
  • 260 Looney R J, Hasan M S, Coffin D. et al . Hepatitis B immunization of healthy elderly adults: relationship between naive CD 4 + T cells and primary immune response and evaluation of GM-CSF as an adjuvant.  J Clin Immunol. 2001;  21 30-36
    Google Scholar
  • 261 Lucey M R, Graham D M, Martin P. et al . Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation.  Gut. 1992;  33 1390-1396
    Google Scholar
  • 262 Madejon A, Cotonat T, Bartolome J. et al . Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response.  Hepatology. 1994;  19 1331-1336
    Google Scholar
  • 263 Manesis E K, Hadziyannis S J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.  Gastroenterology. 2001;  121 101-109
    Google Scholar
  • 264 Manns M P, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications.  Gut. 2006;  55 1350-1359
    Google Scholar
  • 265 Manzarbeitia C, Reich D J, Ortiz J A. et al . Safe use of livers from donors with positive hepatitis B core antibody.  Liver Transpl. 2002;  8 556-561
    Google Scholar
  • 266 Marangi A L, Giordano R, Montanaro A. et al . Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination.  Am J Kidney Dis. 1994;  23 537-542
    Google Scholar
  • 267 Marcellin P, Boyer N, Colin J F. et al . Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine.  Gut. 1993;  34 S106
    Google Scholar
  • 268 Marcellin P, Chang T T, Lim S G. et al . Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients.  Hepatology. 2006;  44 548A
    Google Scholar
  • 269 Marcellin P, Chang T T, Lim S G. et al . Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.  N Engl J Med. 2003;  348 808-816
    Google Scholar
  • 270 Marcellin P, Lau G K, Bonino F. et al . Peginterferon alpha-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.  N Engl J Med. 2004;  351 1206-1217
    Google Scholar
  • 271 Margreiter R, Kramar R, Huber C. et al . Combined liver and kidney transplantation.  Lancet. 1984;  1 1077-1078
    Google Scholar
  • 272 Maria Elzbieta S L, Marek L D. Histological outcome of chronic hepatitis B in children treated with interferon alpha.  World J Gastroenterol. 2005;  11 7179-7182
    Google Scholar
  • 273 Markovic S, Drozina G, Vovk M. et al . Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.  Hepatogastroenterology. 1999;  46 2925-2930
    Google Scholar
  • 274 Markowitz J S, Martin P, Conrad A J. et al . Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.  Hepatology. 1998;  28 585-589
    Google Scholar
  • 275 Martinez E, Blanco J L, Arnaiz J A. et al . Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.  AIDS. 2001;  15 1261-1268
    Google Scholar
  • 276 Marusawa H, Chiba T. How can we prevent viral reactivation in liver transplantation from donors with latent hepatitis B virus infection?.  J Gastroenterol. 2001;  36 212-213
    Google Scholar
  • 277 Marzano A, Salizzoni M, Debernardi-Venon W. et al . Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis.  J Hepatol. 2001;  34 903-910
    Google Scholar
  • 278 Mason W S, Taylor J M. Liver transplantation: a model for the transmission of hepatitis delta virus.  Gastroenterology. 1991;  101 1741-1743
    Google Scholar
  • 279 Mast E E, Weinbaum C M, Fiore A E. et al . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.  MMWR Recomm Rep. 2006;  55 1-33
    Google Scholar
  • 280 Mathurin P, Mouquet C, Poynard T. et al . Impact of hepatitis B and C virus on kidney transplantation outcome.  Hepatology. 1999;  29 257-263
    Google Scholar
  • 281 Mathurin P, Thibault V, Kadidja K. et al . Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections.  J Viral Hepat. 2000;  7 15-22
    Google Scholar
  • 282 McDonald J A, Harris S, Waters J A. et al . Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display.  J Hepatol. 1987;  4 337-342
    Google Scholar
  • 283 McMahon B J, Alward W L, Hall D B. et al . Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.  J Infect Dis. 1985;  151 599-603
    Google Scholar
  • 284 Mertens T, Haller O A, Klenk H D. Diagnostik und Therapie von Viruskrankheiten: Leitlinien der Gesellschaft für Virologie. Munich; Urban und Fischer-Verlag 2004
    Google Scholar
  • 285 Mettang T, Schenk U, Thomas S. et al . Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study.  Nephron. 1996;  72 192-196
    Google Scholar
  • 286 Miro J M, Laguno M, Moreno A. et al . Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)?.  J Hepatol. 2006;  44 S140-S145
    Google Scholar
  • 287 Mitsui T, Iwano K, Suzuki S. et al . Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls.  Hepatology. 1989;  10 324-327
    Google Scholar
  • 288 Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling.  Nephron. 1996;  73 417-420
    Google Scholar
  • 289 Monteyne P, Andre F E. Is there a causal link between hepatitis B vaccination and multiple sclerosis?.  Vaccine. 2000;  18 1994-2001
    Google Scholar
  • 290 Mutchnick M G, Lindsay K L, Schiff E R. et al . Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.  J Viral Hepat. 1999;  6 397-403
    Google Scholar
  • 291 Myers R P, Tainturier M H, Ratziu V. et al . Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.  J Hepatol. 2003;  39 222-230
    Google Scholar
  • 292 Nagamatsu H, Itano S, Nagaoka S. et al . Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.  Am J Gastroenterol. 2004;  99 2369-2375
    Google Scholar
  • 293 Nagamatsu H, Kumashiro R, Itano S. et al . Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC.  Hepatol Res. 2003;  26 293-301
    Google Scholar
  • 294 Nakamura Y, Motokura T, Fujita A. et al . Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987 - 1991.  Cancer. 1996;  78 2210-2215
    Google Scholar
  • 295 Neff G W, Bonham A, Tzakis A G. et al . Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.  Liver Transpl. 2003;  9 239-247
    Google Scholar
  • 296 Neff G W, Nery J, Lau D T. et al . Tenofovir therapy for lamivudine resistance following liver transplantation.  Ann Pharmacother. 2004;  38 1999-2004
    Google Scholar
  • 297 Neumann U P, Lang M, Moldenhauer A. et al . Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation.  Transplantation. 2001;  71 1163-1168
    Google Scholar
  • 298 Ni Y H, Huang F C, Wu T C. et al . lamivudinee treatment in maternally transmitted chronic hepatitis B virus infection patients.  Pediatr Int. 2005;  47 372-377
    Google Scholar
  • 299 Niederau C, Heintges T, Lange S. et al . Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B.  N Engl J Med. 1996;  334 1422-1427
    Google Scholar
  • 300 Niro G A, Ciancio A, Gaeta G B. et al . Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.  Hepatology. 2006;  44 713-720
    Google Scholar
  • 301 Ohtsu T, Sai T, Oka M. et al . Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies.  Jpn J Clin Oncol. 1991;  21 360-365
    Google Scholar
  • 302 Olausson M, Mjornstedt L, Norden G. et al . Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients.  Am J Transplant. 2007;  7 130-136
    Google Scholar
  • 303 Ollenschlager G, Kopp I, Lelgemann M. et al . The German program for disease management guidelines. Background, methods, and development process.  Med Klin. 2006;  101 840-845
    Google Scholar
  • 304 Onozawa M, Hashino S, Izumiyama K. et al . Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection.  Transplantation. 2005;  79 616-619
    Google Scholar
  • 305 Ozgenc F, Arikan C, Sertoz R Y. et al . Effect of long-term lamivudine in chronic hepatitis B virus-infected children.  Antivir Ther. 2004;  9 729-732
    Google Scholar
  • 306 Ozguroglu M, Bilici A, Turna H. et al . Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin"s lymphoma.  Med Oncol. 2004;  21 67-72
    Google Scholar
  • 307 Palmer D R, Perry K R, Mortimer P P. et al . Variation in the sensitivity of HBsAg screening kits.  Transfus Med. 1996;  6 311-317
    Google Scholar
  • 308 Papatheodoridis G V, Dimou E, Laras A. et al . Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.  Hepatology. 2002;  36 219-226
    Google Scholar
  • 309 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.  J Hepatol. 2001;  34 306-313
    Google Scholar
  • 310 Park J W, Park K W, Cho S H. et al . Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study.  Am J Gastroenterol. 2005;  100 2194-2200
    Google Scholar
  • 311 Pastore G, Santantonio T, Monno L. et al . Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B.  Hepatogastroenterology. 1988;  35 57-61
    Google Scholar
  • 312 Perrillo R, Hann H W, Mutimer D. et al . Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.  Gastroenterology. 2004;  126 81-90
    Google Scholar
  • 313 Perrillo R P, Lai C L, Liaw Y F. et al . Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.  Hepatology. 2002;  36 186-194
    Google Scholar
  • 314 Perrillo R P, Wright T, Rakela J. et al . A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.  Hepatology. 2001;  33 424-432
    Google Scholar
  • 315 Persico M, De Marino F, Russo G D. et al . Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.  Blood. 2002;  99 724-725
    Google Scholar
  • 316 Perz J F, Armstrong G L, Farrington L A. et al . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.  J Hepatol. 2006;  45 529-538
    Google Scholar
  • 317 Peters M G, Andersen J, Lynch P. et al . Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A 5127.  Hepatology. 2006;  44 1110-1116
    Google Scholar
  • 318 Peters M G, Hann H H, Martin P. et al . Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.  Gastroenterology. 2004;  126 91-101
    Google Scholar
  • 319 Pineda J A, Romero-Gomez M, Diaz-Garcia F. et al . HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.  Hepatology. 2005;  41 779-789
    Google Scholar
  • 320 Pirson Y, Alexandre G P, Ypersele C. Long-term effect of HBs antigenemia on patient survival after renal transplantation.  N Engl J Med. 1977;  296 194-196
    Google Scholar
  • 321 Poge U, Gerhardt T, Palmedo H. et al . MDRD equations for estimation of GFR in renal transplant recipients.  Am J Transplant. 2005;  5 1306-1311
    Google Scholar
  • 322 Pol S, Wesenfelder L, Dubois F. et al . Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers.  J Viral Hepat. 1994;  1 131-137
    Google Scholar
  • 323 Pollicino T, Squadrito G, Cerenzia G. et al . Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.  Gastroenterology. 2004;  126 102-110
    Google Scholar
  • 324 Pontisso P, Ruvoletto M G, Fattovich G. et al . Clinical and virological profiles in patients with multiple hepatitis virus infections.  Gastroenterology. 1993;  105 1529-1533
    Google Scholar
  • 325 Poynard T, Zoulim F, Ratziu V. et al . Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.  Am J Gastroenterol. 2005;  100 1970-1980
    Google Scholar
  • 326 Prakoso E, Strasser S I, Koorey D J. et al . Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.  Clin Transplant. 2006;  20 369-373
    Google Scholar
  • 327 Pramoolsinsap C, Poovorawan Y, Hirsch P. et al . Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV.  Ann Trop Med Parasitol. 1999;  93 745-751
    Google Scholar
  • 328 Prieto M, Gomez M D, Berenguer M. et al . De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.  Liver Transpl. 2001;  7 51-58
    Google Scholar
  • 329 Propst T, Propst A, Lhotta K. et al . Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination.  Am J Kidney Dis. 1998;  32 1041-1045
    Google Scholar
  • 330 Protzer-Knolle U, Naumann U, Bartenschlager R. et al . Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation.  Hepatology. 1998;  27 254-263
    Google Scholar
  • 331 Puoti M, Airoldi M, Bruno R. et al . Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.  AIDS Rev. 2002;  4 27-35
    Google Scholar
  • 332 Puoti M, Cozzi-Lepri A, Arici C. et al . Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.  Antivir Ther. 2006;  11 567-574
    Google Scholar
  • 333 Puoti M, Torti C, Bruno R. et al . Natural history of chronic hepatitis B in co-infected patients.  J Hepatol. 2006;  44 S65-S70
    Google Scholar
  • 334 Ragni M V, Belle S H, Im K. et al . Survival of human immunodeficiency virus-infected liver transplant recipients.  J Infect Dis. 2003;  188 1412-1420
    Google Scholar
  • 335 Ragni M V, Eghtesad B, Schlesinger K W. et al . Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease.  Liver Transpl. 2005;  11 1425-1430
    Google Scholar
  • 336 Rahman F, Dahmen A, Herzog-Hauff S. et al . Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.  Hepatology. 2000;  31 521-527
    Google Scholar
  • 337 Raimondo G, Pollicino T, Cacciola I. et al . Occult hepatitis B virus infection.  J Hepatol. 2007;  46 160-170
    Google Scholar
  • 338 Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission.  Expert Rev Anti Infect Ther. 2004;  2 133-145
    Google Scholar
  • 339 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection.  Nat Rev Immunol. 2005;  5 215-229
    Google Scholar
  • 340 Rendi-Wagner P, Wiedermann G, Stemberger H. et al . New vaccination strategies for low- and non-responders to hepatitis B vaccine.  Wien Klin Wochenschr. 2002;  114 175-180
    Google Scholar
  • 341 Resti M, Azzari C, Mannelli F. et al . Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?.  Vaccine. 1997;  15 1338-1340
    Google Scholar
  • 342 Rizzetto M. Hepatitis D: virology, clinical and epidemiological aspects.  Acta Gastroenterol Belg. 2000;  63 221-224
    Google Scholar
  • 343 Rizzetto M. Hepatitis delta: the virus and the disease.  J Hepatol. 1990;  11 (Suppl 1] S145-S148
    Google Scholar
  • 344 Rizzetto M, Macagno S, Chiaberge E. et al . Liver transplantation in hepatitis delta virus disease.  Lancet. 1987;  2 469-471
    Google Scholar
  • 345 Rizzetto M, Verme G, Recchia S. et al . Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment.  Ann Intern Med. 1983;  98 437-441
    Google Scholar
  • 346 Robert-Koch Institut . Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2005.  Epidem Bull. 2006;  46
    Google Scholar
  • 347 Robert-Koch Institut . Mitteilungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut: Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen.  Epidem Bull. 2004;  6 33-52
    Google Scholar
  • 348 Robert-Koch Institut . Virushepatitis B, C und D im Jahre 2004.  Epidem Bull. 2005;  46 421-436
    Google Scholar
  • 349 Robert-Koch Institut . Empfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut/Stand Juli 2006.  Epidem Bull. 2006;  30 235-254
    Google Scholar
  • 350 Roche B, Samuel D, Gigou M. et al . De novo and apparent de novo hepatitis B virus infection after liver transplantation.  J Hepatol. 1997;  26 517-526
    Google Scholar
  • 351 Rockstroh J K. Influence of viral hepatitis on HIV infection.  J Hepatol. 2006;  44 S25-S27
    Google Scholar
  • 352 Rodella A, Galli C, Terlenghi L. et al . Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B.  J Clin Virol. 2006;  37 206-212
    Google Scholar
  • 353 Romand F, Michallet M, Pichoud C. et al . Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B.  Gastroenterol Clin Biol. 1999;  23 770-774
    Google Scholar
  • 354 Roque-Afonso A M, Feray C, Samuel D. et al . Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.  Gut. 2002;  50 95-99
    Google Scholar
  • 355 Rosenau J, Bahr M J, Tillmann H L. et al . lamivudinee and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.  J Hepatol. 2001;  34 895-902
    Google Scholar
  • 356 Rosenau J, Hooman N, Rifai K. et al . Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response.  Transpl Int. 2006;  19 828-833
    Google Scholar
  • 357 Rosina F, Pintus C, Meschievitz C. et al . A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study.  Hepatology. 1991;  13 1052-1056
    Google Scholar
  • 358 Rosina F, Rizzetto M. Treatment of chronic type D (delta) hepatitis with alpha interferon.  Semin Liver Dis. 1989;  9 264-266
    Google Scholar
  • 359 Rosman A S, Basu P, Galvin K. et al . Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial.  Am J Med. 1997;  103 217-222
    Google Scholar
  • 360 Rossi G, Pelizzari A, Motta M. et al . Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.  Br J Haematol. 2001;  115 58-62
    Google Scholar
  • 361 Ruiz R, Kunitake H, Wilkinson A H. et al . Long-term analysis of combined liver and kidney transplantation at a single center.  Arch Surg. 2006;  141 735-741
    Google Scholar
  • 362 Ryu S H, Chung Y H, Choi M H. et al . Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.  J Hepatol. 2003;  39 614-619
    Google Scholar
  • 363 Sadovnick A D, Scheifele D W. School-based hepatitis B vaccination programme and adolescent multiple sclerosis.  Lancet. 2000;  355 549-550
    Google Scholar
  • 364 Sagnelli E, Coppola N, Scolastico C. et al . Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis.  Hepatology. 2000;  32 1106-1110
    Google Scholar
  • 365 Sagnelli E, Pasquale G, Coppola N. et al . Influence of chronic coinfection with hepatitis B and C virus on liver histology.  Infection. 2004;  32 144-148
    Google Scholar
  • 366 Sakallioglu O, Gok F, Kalman S. et al . Hepatitis B complicated focal segmental glomerulosclerosis.  J Nephrol. 2005;  18 433-435
    Google Scholar
  • 367 Saltik-Temizel I N, Kocak N, Demir H. Interferon-alpha and lamivudine combination therapy of children with chronic hepatitis b infection who were interferon-alpha nonresponders.  Pediatr Infect Dis J. 2004;  23 466-468
    Google Scholar
  • 368 Saltik-Temizel I N, Kocak N, Demir H. lamivudinee and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection.  J Clin Gastroenterol. 2005;  39 68-70
    Google Scholar
  • 369 Samuel D, Muller R, Alexander G. et al . Liver transplantation in European patients with the hepatitis B surface antigen.  N Engl J Med. 1993;  329 1842-1847
    Google Scholar
  • 370 Samuel D, Zignego A L, Reynes M. et al . Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.  Hepatology. 1995;  21 333-339
    Google Scholar
  • 371 Sanchez-Fueyo A, Rimola A, Grande L. et al . Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.  Hepatology. 2000;  31 496-501
    Google Scholar
  • 372 Saracco G, Rosina F, Brunetto M R. et al . Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection.  J Hepatol. 1987;  5 274-281
    Google Scholar
  • 373 Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb.  J Infect Chemother. 2005;  11 189-191
    Google Scholar
  • 374 Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines.  Vaccine. 2005;  23 3876-3886
    Google Scholar
  • 375 Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection.  J Med Virol. 2006;  78 (Suppl 1] S66-S70
    Google Scholar
  • 376 Schiff E R, Lai C L, Hadziyannis S. et al . Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.  Hepatology. 2003;  38 1419-1427
    Google Scholar
  • 377 Schildgen O, Sirma H, Funk A. et al . Variant of hepatitis B virus with primary resistance to adefovir.  N Engl J Med. 2006;  354 1807-1812
    Google Scholar
  • 378 Schirmacher P, Fleig W E, Tannapfel A. et al . Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet).  Pathologe. 2004;  25 337-348
    Google Scholar
  • 379 Schmilovitz-Weiss H, Ben Ari Z, Sikuler E. et al . lamivudinee treatment for acute severe hepatitis B: a pilot study.  Liver Int. 2004;  24 547-551
    Google Scholar
  • 380 Schmutz G, Nelson M, Lutz T. et al . Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.  AIDS. 2006;  20 1951-1954
    Google Scholar
  • 381 Seaworth B, Drucker J, Starling J. et al . Hepatitis B vaccines in patients with chronic renal failure before dialysis.  J Infect Dis. 1988;  157 332-337
    Google Scholar
  • 382 Segovia R, Sanchez-Fueyo A, Rimola A. et al . Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation.  Liver Transpl. 2001;  7 106-112
    Google Scholar
  • 383 Seth P, Alrajhi A A, Kagevi I. et al . Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease.  Bone Marrow Transplant. 2002;  30 189-194
    Google Scholar
  • 384 Shattock A G, Morris M C. Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies.  J Clin Microbiol. 1991;  29 1873-1876
    Google Scholar
  • 385 Sheldon J, Camino N, Rodes B. et al . Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.  Antivir Ther. 2005;  10 727-734
    Google Scholar
  • 386 Sheldon J A, Corral A, Rodes B. et al . Risk of selecting K 65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.  AIDS. 2005;  19 2036-2038
    Google Scholar
  • 387 Sheng W H, Hung C C, Kao J H. et al . Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.  Clin Infect Dis. 2007;  44 988-995
    Google Scholar
  • 388 Sherman M, Peltekian K M, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.  Hepatology. 1995;  22 432-438
    Google Scholar
  • 389 Sherman M, Yurdaydin C, Sollano J. et al . Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.  Gastroenterology. 2006;  130 2039-2049
    Google Scholar
  • 390 Shibolet O, Ilan Y, Gillis S. et al . lamivudinee therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.  Blood. 2002;  100 391-396
    Google Scholar
  • 391 Silvestri F, Sperotto A, Ermacora A. et al . lamivudinee for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report.  Haematologica. 2000;  85 327-329
    Google Scholar
  • 392 Smedile A, Farci P, Verme G. et al . Influence of delta infection on severity of hepatitis B.  Lancet. 1982;  2 945-947
    Google Scholar
  • 393 Sokal E. Drug treatment of pediatric chronic hepatitis B.  Paediatr Drugs. 2002;  4 361-369
    Google Scholar
  • 394 Sokal E M, Kelly D A, Mizerski J. et al . Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.  Hepatology. 2006;  43 225-232
    Google Scholar
  • 395 Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients.  J Antimicrob Chemother. 2006;  57 815-818
    Google Scholar
  • 396 Soriano V, Puoti M, Bonacini M. et al . Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.  AIDS. 2005;  19 221-240
    Google Scholar
  • 397 Spengler U, Lichterfeld M, Rockstroh J K. Antiretroviral drug toxicity - a challenge for the hepatologist?.  J Hepatol. 2002;  36 283-294
    Google Scholar
  • 398 Sponseller C A, Bacon B R, Di Bisceglie A M. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.  Liver Transpl. 2000;  6 715-720
    Google Scholar
  • 399 Starkel P, Stoffel M, Lerut J. et al . Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.  Liver Transpl. 2005;  11 1228-1234
    Google Scholar
  • 400 Steinmuller T, Seehofer D, Rayes N. et al . Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease.  Hepatology. 2002;  35 1528-1535
    Google Scholar
  • 401 Stevens C E, Alter H J, Taylor P E. et al . Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.  N Engl J Med. 1984;  311 496-501
    Google Scholar
  • 402 Su C W, Huang Y H, Huo T I. et al . Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients.  Gastroenterology. 2006;  130 1625-1635
    Google Scholar
  • 403 Su G G, Pan K H, Zhao N F. et al . Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy.  World J Gastroenterol. 2004;  10 910-912
    Google Scholar
  • 404 Sung J JY, Lai J Y, Zeuzem S. et al . A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis.  Journal of Hepatology. 2003;  38 25-26
    Google Scholar
  • 405 Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America.  J Med Virol. 2006;  78 (Suppl 1] S43-S47
    Google Scholar
  • 406 Tang J R, Cova L, Lamelin J P. et al . Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction.  J Hepatol. 1994;  21 953-960
    Google Scholar
  • 407 Tassopoulos N C, Papaevangelou G J, Sjogren M H. et al . Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.  Gastroenterology. 1987;  92 1844-1850
    Google Scholar
  • 408 Tenderich G, Zittermann A, Prohaska W. et al . Frequent detection of hepatitis B core antibodies in heart transplant recipients without preceding hepatitis B infection.  Transplant Proc. 2005;  37 4522-4524
    Google Scholar
  • 409 Tenney D, Baldick C J, Rose R E. et al . Only a subset of HBV substitutions at entecavir resistance residues lead to phenotypic resistance and virologic rebound.  Hepatology. 2006;  44 253A-254A
    Google Scholar
  • 410 ter Borg F, Smorenburg S, Man R A. et al . Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.  Dig Dis Sci. 1998;  43 2267-2270
    Google Scholar
  • 411 Terrault de N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective.  Liver Transpl. 2005;  11 716-732
    Google Scholar
  • 412 Thierfelder W, Hellenbrand W, Meisel H. et al . Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998.  Eur J Epidemiol. 2001;  17 429-435
    Google Scholar
  • 413 Thio C L. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment.  Semin Liver Dis. 2003;  23 125-136
    Google Scholar
  • 414 Thio C L, Seaberg E C, Skolasky Jr R. et al . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).  Lancet. 2002;  360 1921-1926
    Google Scholar
  • 415 Thomas H C, Lemon S, Zuckerman A J. Viral Hepatitis. Thomas HC, Lemon S, Zuckerman AJ Blackwell Publishing 2005
    Google Scholar
  • 416 Tillmann H L, Hadem J, Leifeld L. et al . Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.  J Viral Hepat. 2006;  13 256-263
    Google Scholar
  • 417 Tseng P L, Lu S N, Tung H D. et al . Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.  J Viral Hepat. 2005;  12 386-392
    Google Scholar
  • 418 Tsutsumi Y, Tanaka J, Kawamura T. et al . Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin"s lymphoma.  Ann Hematol. 2004;  83 58-60
    Google Scholar
  • 419 Uemoto S, Inomata Y, Sannomiya A. et al . Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors.  Transplant Proc. 1998;  30 134-135
    Google Scholar
  • 420 Bommel van F, Wunsche T, Mauss S. et al . Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.  Hepatology. 2004;  40 1421-1425
    Google Scholar
  • 421 Bommel van F, Zollner B, Sarrazin C. et al . Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.  Hepatology. 2006;  44 318-325
    Google Scholar
  • 422 Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board.  BMJ. 1997;  314 1033-1036
    Google Scholar
  • 423 Nunen A B, Hansen B E, Suh D J. et al . Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.  Gut. 2003;  52 420-424
    Google Scholar
  • 424 Zonneveld van M, Nunen van A B, Niesters H G. et al . lamivudinee treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.  J Viral Hepat. 2003;  10 294-297
    Google Scholar
  • 425 Vassiliadis van T, Garipidou V, Tziomalos K. et al . Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series.  Am J Hematol. 2005;  80 197-203
    Google Scholar
  • 426 Verme G, Brunetto M R, Oliveri F. et al . Role of hepatitis delta virus infection in hepatocellular carcinoma.  Dig Dis Sci. 1991;  36 1134-1136
    Google Scholar
  • 427 Villa E, Grottola A, Buttafoco P. et al . High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.  Am J Gastroenterol. 2001;  96 2973-2977
    Google Scholar
  • 428 Villeneuve E, Vincelette J, Villeneuve J P. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation.  Can J Gastroenterol. 2000;  14 (Suppl B) 59B-62B
    Google Scholar
  • 429 Villeneuve J P, Condreay L D, Willems B. et al . lamivudinee treatment for decompensated cirrhosis resulting from chronic hepatitis B.  Hepatology. 2000;  31 207-210
    Google Scholar
  • 430 Villeneuve J P, Durantel D, Durantel S. et al . Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.  J Hepatol. 2000;  39 1085-1089
    Google Scholar
  • 431 Vo T hi DH, Bourgois A, Bontems P. et al . Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls.  J Pediatr Gastroenterol Nutr. 2005;  40 141-145
    Google Scholar
  • 432 Wai C T, Chu C J, Hussain M. et al . HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.  Hepatology. 2002;  36 1425-1430
    Google Scholar
  • 433 Wainwright R B, Bulkow L R, Parkinson A J. et al . Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study.  J Infect Dis. 1997;  175 674-677
    Google Scholar
  • 434 Waked I, Amin M, Abd e F. et al . Experience with interferon in chronic hepatitis B in Egypt.  J Chemother. 1990;  2 310-318
    Google Scholar
  • 435 Walker U A, Bauerle J, Laguno M. et al . Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.  Hepatology. 2004;  39 311-317
    Google Scholar
  • 436 Walter J, Radun D, Claus H. et al . Hepatitis B and C risk factors in Germany - results of the national surveillance.  Gesundheitswesen. 2005;  67 441-447
    Google Scholar
  • 437 Wands J R, Chura C M, Roll F J. et al . Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders.  Gastroenterology. 1975;  68 105-112
    Google Scholar
  • 438 Wartelle-Bladou C, Lafon J, Trepo C. et al . Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection.  J Hepatol. 2001;  34 774-779
    Google Scholar
  • 439 Watson B, West D J, Chilkatowsky A. et al . Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine.  Vaccine. 2001;  19 3164-3168
    Google Scholar
  • 440 Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact.  J Clin Virol. 2005;  32 102-112
    Google Scholar
  • 441 Wedemeyer H, Cornberg M, Tegtmeyer B. et al . Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication.  Clin Microbiol Infect. 2004;  10 70-72
    Google Scholar
  • 442 Weltman M D, Brotodihardjo A, Crewe E B. et al . Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.  J Viral Hepat. 1995;  2 39-45
    Google Scholar
  • 443 Wen Y K, Chen M L. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy.  Clin Nephrol. 2006;  65 211-215
    Google Scholar
  • 444 West D J, Calandra G B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination.  Vaccine. 1996;  14 1019-1027
    Google Scholar
  • 445 Westhoff T H, Jochimsen F, Schmittel A. et al . Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.  Blood. 2003;  102 1930
    Google Scholar
  • 446 Westland C, Delaney W, Yang H. et al . Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.  Gastroenterology. 2003;  125 107-116
    Google Scholar
  • 447 Westland C E, Yang H, Delaney W E. et al . Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.  Hepatology. 2003;  38 96-103
    Google Scholar
  • 448 Whittle H, Jaffar S, Wansbrough M. et al . Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children.  BMJ. 2002;  325 569
    Google Scholar
  • 449 Wiegand J, Hasenclever D, Tillman H L. Should treatment of hepatitis B depend on HBV genotypes? - A hypothesis generated from an explorative analysis of published evidence.  Hepatology. 2006;  44 564A-565A
    Google Scholar
  • 450 Williams R. Global challenges in liver disease.  Hepatology. 2006;  44 521-526
    Google Scholar
  • 451 Wintermeyer P, Gerner P, Gehring S. et al . Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children.  World J Gastroenterol. 2006;  12 2235-2238
    Google Scholar
  • 452 Wismans P, Hattum van J, Stelling T. et al . Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination.  Hepatogastroenterology. 1988;  35 78-79
    Google Scholar
  • 453 Wit F W, Weverling G J, Weel J. et al . Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.  J Infect Dis. 2002;  186 23-31
    Google Scholar
  • 454 Wolters L M, Nunen A B, Honkoop van P. et al . lamivudinee-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus.  J Viral Hepat. 2000;  7 428-434
    Google Scholar
  • 455 Wong D K, Cheung A M, O"Rourke K. et al . Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.  Ann Intern Med. 1993;  119 312-323
    Google Scholar
  • 456 Wong D K, Yim C, Naylor C D. et al . Interferon alpha treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population.  Gastroenterology. 1995;  108 165-171
    Google Scholar
  • 457 Wong V W, Chan H L, Wong M L. et al . Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.  Aliment Pharmacol Ther. 2004;  19 323-329
    Google Scholar
  • 458 World Health Organisation . Hepatitis Delta.  Electronic Citation. 2001;  , http://www.who.int/csr/
    Google Scholar
  • 459 World Health Organisation . Hepatitis B.  Electronic Citation. 2002;  , http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf
    Google Scholar
  • 460 Wursthorn K, Buggisch P, Lutgehetmann M. et al . Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.  Antivir Ther. 2006;  11 647-652
    Google Scholar
  • 461 Wursthorn K, Lutgehetmann M, Dandri M. et al . Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.  Hepatology. 2006;  44 675-684
    Google Scholar
  • 462 Yang B, Zhang B, Xu Y. et al . Prospective study of early detection for primary liver cancer.  J Cancer Res Clin Oncol. 1997;  123 357-360
    Google Scholar
  • 463 Yang H I, Lu S N, Liaw Y F. et al . Hepatitis B e antigen and the risk of hepatocellular carcinoma.  N Engl J Med. 2002;  347 168-174
    Google Scholar
  • 464 Yao F Y, Terrault N A, Freise C. et al . lamivudinee treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.  Hepatology. 2001;  34 411-416
    Google Scholar
  • 465 Yeo W, Chan P K, Ho W M. et al . lamivudinee for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.  J Clin Oncol. 2004;  22 927-934
    Google Scholar
  • 466 Yeo W, Chan P K, Zhong S. et al . Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.  J Med Virol. 2000;  62 299-307
    Google Scholar
  • 467 Yeo W, Johnson P J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.  Hepatology. 2006;  43 209-220
    Google Scholar
  • 468 Yeo W, Steinberg J L, Tam J S. et al . lamivudinee in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.  J Med Virol. 1999;  59 263-269
    Google Scholar
  • 469 Yeo W, Zee B, Zhong S. et al . Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.  Br J Cancer. 2004;  90 1306-1311
    Google Scholar
  • 470 Yu A S, Vierling J M, Colquhoun S D. et al . Transmission of hepatitis B infection from hepatitis B core antibody - positive liver allografts is prevented by lamivudine therapy.  Liver Transpl. 2001;  7 513-517
    Google Scholar
  • 471 Yuen M F, Sablon E, Hui C K. et al . Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.  Hepatology. 2001;  34 785-791
    Google Scholar
  • 472 Yurdaydin C, Bozkaya H, Gurel S. et al . Famciclovir treatment of chronic delta hepatitis.  J Hepatol. 2002;  37 266-271
    Google Scholar
  • 473 Yurdaydin C, Wedemeyer H, Zachou K. et al . A multicenter randomised study comparing the efficacy of pegylated interferon-alpha-2a plus adefovir dipivoxil vs. pegylated interferon-alpha-2a plus placebo vs. adefovir dipivoxil for the treatment of chronic delta hepatitis.  Hepatology. 2006;  44 230A
    Google Scholar
  • 474 Zanetti A R, Mariano A, Romano L. et al . Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.  Lancet. 2005;  366 1379-1384
    Google Scholar
  • 475 Zarski J P, Bohn B, Bastie A. et al . Characteristics of patients with dual infection by hepatitis B and C viruses.  J Hepatol. 1998;  28 27-33
    Google Scholar
  • 476 Zavaglia C, Severini R, Tinelli C. et al . A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.  Dig Dis Sci. 2000;  45 690-696
    Google Scholar
  • 477 Zignego A L, Fontana R, Puliti S. et al . Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.  Arch Virol. 1997;  142 535-544
    Google Scholar
  • 478 Zollner B, Schafer P, Feucht H H. et al . Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy.  J Med Virol. 2001;  65 659-663
    Google Scholar
  • 479 Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.  J Hepatol. 2005;  42 302-308
    Google Scholar
  • 480 Zuccotti G V, Cucchi C, Gracchi V. et al . A 1-year trial of lamivudine for chronic hepatitis B in children.  J Int Med Res. 2002;  30 200-202
    Google Scholar
  • 481 Zylberberg H, Jiang J, Pialoux G. et al . Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients.  Gastroenterol Clin Biol. 1996;  20 968-971
    Google Scholar

1 Original publication: Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-) Infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 2007; 45 (6): 525 - 574.

Prof. Dr. Michael P. Manns

Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

Carl-Neuberg Str. 1

30625 Hannover

Email: manns.michael@mh-hannover.de